Case Report: Severe COVID-19 with Late-Onset Sepsis-like Illness in a Neonate

Suryadi Nicolaas Napoleon Tatura*

Division of Pediatric Infection and Tropical Medicine, Department of Pediatrics, Faculty of Medicine, Sam Ratulangi University, Manado, Indonesia; Department of Pediatrics, Prof. R. D. Kandou General Hospital, Manado, North Sulawesi, Indonesia; Department of Pediatrics, Robert Wolter Mongisidi Army Hospital, Manado, North Sulawesi, Indonesia

Abstract. A case of severe COVID-19 with late-onset sepsis-like illness is presented in a neonate. A male infant was born to a mother with mild COVID-19 symptoms and positive IgG anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) through spontaneous vaginal delivery. He and his mother were then confirmed to have SARS-CoV-2 infection. His condition was stable and discharge from the hospital was planned. However, on day 6 of care, his condition deteriorated, and after treatment with the COVID-19 protocol and antibiotic administration (because neonatal sepsis had not been ruled out), his condition gradually improved and he was discharged in good clinical condition without any sequelae. The pitfalls of this case are the presence of late-onset severe COVID-19, and the difficulty in monitoring patients in isolation rooms, which makes it challenging to differentiate and manage therapy between severe COVID-19 and neonatal sepsis. The similarities between the presentation of sepsis and severe COVID-19 require a thorough anamnesis, careful observation, and a thorough workup for alternative causes of sepsis to be able to make wise antibiotic treatment decisions, to prevent mismanagement, and to reduce morbidity and mortality, especially in developing countries such as Indonesia.

INTRODUCTION

From the beginning of the pandemic until August 2021, Indonesian data show that 6 of 1,000 Indonesian children age 0 to 18 years are positive for COVID-19 using a reverse transcription–polymerase chain reaction (RT-PCR) test, and neonates are a group that is prone to serious illness and death.1,2 In addition, sepsis is still a health problem that has high morbidity and mortality in Asia, including Indonesia.3,4

COVID-19 in pediatric patients is mostly mild or asymptomatic.5 However, a previous study of neonates reported that in 25 cases of COVID-19, 80% of patients were asymptomatic, and those who were severely ill included a greater proportion of neonates than children more than 1 month-old (12% versus 2%).6 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spreads rapidly in children, suggesting that it has a strong transmission capacity in neonates.7 Neonates are thought to be more susceptible to SARS-CoV-2 because their immune system is not well developed.8 Some studies reported that the most common symptoms of neonates with confirmed COVID-19 were respiratory distress, fever, and feeding intolerance, such as in neonatal pneumonia.7 Similar to other viruses, such as entoroviral and herpes simplex virus infections, the infected neonates with this condition will have clinical presentations similar to neonatal sepsis caused by bacteria, and it can be very challenging to distinguish among them.9–11 Therefore, it is important to do thorough investigations for bacterial causes in every confirmed COVID-19 case. To the best of our knowledge, this is the first reported case of COVID-19 that presented with late-onset neonatal sepsis.

CASE PRESENTATION

A male infant was born on November 29, 2020 from a mother with suspected COVID-19 infection based on positive serological confirmation with positive IgG anti-SARS-CoV-2 of the mother before delivery at Wolter Mongisidi Army Hospital, Manado. The mother was confirmed to have SARS-COV-2 by RT-PCR on the day after delivery. The infant was born via spontaneous vaginal delivery, at a gestational age of 37 to 38 weeks. His birth weight was 3,200 g and his length was 48 cm. The newborn’s Apgar score at minute 1 was 7 points and at minute 5 was 9 points. After birth, the newborn cried immediately, appeared active, and had no shortness of breath. The temperature of the newborn was 36.9°C, with a respiratory rate of 40 cycles/min, a pulse rate of 146 beats/min, and a saturated oxygen level of 99%.

Other physical examination findings were normal. The blood result on the first day of life was hemoglobin, 16.8 mg/dL; hematocrit, 49.2%; leucocyte count, 9,800 leucocytes/μL; thrombocyte count, 285,000 thrombocytes/μL; neutrophile-to-lymphocyte ratio, 3.6; total lymphocyte count, 2,116 lymphocytes, and C-reactive protein, < 6 mg/dL. Chest radiography showed normal results (Figure 1). The next day (< 24 hours), the patient was tested for SARS-CoV-2, and the result of RT-PCR examination was positive on day 3. He was diagnosed as a term infant with an appropriate gestational age, with confirmed COVID-19, and was asymptomatic. This patient’s status was categorized as congenital COVID-19 based on positive serological confirmation with positive IgG anti-SARS-CoV-2 of the mother before delivery and a positive RT-PCR SARS-CoV-2 result in the infant. The mother and newborn shared the same room. The mother wore a mask and performed hand hygiene when performing hands-on care. When not taking care of her baby directly, she maintained a physical distance from her infant of more than 2 m. The newborn was fed milk formula because the mother’s milk was still lacking during the first 3 days after delivery. The baby’s weight decreased from 3,200 g at birth to 3,000 g on day 3. In general, infants born spontaneously who are in good condition are treated for 1 day only. However, because the protocol required screening, mother and baby were discharged on day 3 of care and were cautioned to self-isolate at home because the infant was in good clinical condition with a normal chest X-ray. Unfortunately, the

*Address correspondence to Suryadi N. N. Tatura, Division of Pediatric Infection and Tropical Medicine, Department of Pediatrics, Faculty of Medicine, Sam Ratulangi University, University, and Prof. R. D. Kandou General Hospital, Jl. Raya Tanawangko No. 56, Manado, North Sulawesi, Indonesia. E-mail: nicolaen_sur@yahoo.co.id
On day 6 of hospitalization, the chest X-ray indicates right pneumonia. Therefore, in this case the administration of antibiotic as required for SARS-COV-2 have been identified in placental cells.12,13 Transmission during delivery through transvaginal and amniotic fluid cannot be ruled out because these tests are not available. Based on previous reports, transvaginal12 and amniotic transmission occurred only in mothers with severe COVID-19 disease or with high blood viral loads.14 Last, postnatal transmission accounts for the majority of infections reported. From days 1 to 5, the infant was stable and in good condition, and chest X-ray results were normal. On day 6, he presented with fever, dyspnea, jaundice, lymphopenia, and a neutrophil-to-lymphocyte ratio of > 3.31. Previous studies reported that neonates who were positive for SARS-CoV-2 had symptoms early in life (early onset), and the most common symptoms were fever, dyspnea, and feeding intolerance. The radiographic findings vary.6,15,16 In contrast to previous reports, our patient experienced late-onset, severe COVID-19. The late onset of severe COVID-19 in our patient can be attributed to the natural course of COVID-19 itself,17 and the possible presence of maternal anti-SARS-CoV2 IgG in infants early in life, according to previous research reports.12,13 Whether administering breast milk containing IgM and IgA SARS-CoV-2 antibodies can prevent severe COVID-19 has not been reported and needs more investigation.18 It is sometimes difficult to distinguish neonatal sepsis from COVID-19 because they have similar clinical manifestations. Table 3 shows the clinical manifestations of neonatal sepsis and COVID-19.19 In this case, the patient had clinical manifestations suggestive of sepsis. It is also difficult to rule out bacteria pneumonia at the start of treatment. Therefore, in this case the administration of antibiotic as
empirical therapy was still given because we could not rule out bacterial infection.\(^\text{20}\)

It is common knowledge that the SARS-CoV-2 virus receptor is present in various organs, so the appearance of clinical manifestations can widely vary, although respiratory symptoms are still the main symptom.\(^\text{21}\)

Jaundice in our patient began to appear on day 4 of treatment, and hyperbilirubinemia increased significantly with worsening of the disease. To our knowledge, the presence of neonatal hyperbilirubinemia in neonatal COVID-19 has not been reported previously. Jaundice may occur in severe COVID-19, but is not a typical symptom in newborns. During the first week of life, more than 60% of newborns in developing countries have jaundice.\(^\text{22}\) The most prevalent risk factors for neonatal jaundice are probably prematurity, hemolytic disease, perinatal infection, and exclusive breastfeeding.\(^\text{23}\) In this case, possible jaundice may be caused by the COVID-19 infection process, pneumonia, and inadequate early food intake resulting from stress and worries from mothers who have COVID-19. The etiopathogenesis of hyperbilirubinemia resulting from COVID-19 infection is hypothesized to occur by two mechanisms. First, there is impaired active transport of bilirubin uptake into the hepatocytes, or liver injury resulting from expression of the ACE-2 receptor as a target for SARS-CoV-2. Second, there is impaired bilirubin excretion in the presence of cholangiocyte injury resulting from greater ACE-2 expression.\(^\text{24}\) Meanwhile, from pneumonia itself, jaundice can be caused by two factors—namely, disturbances in the nutritional status of the liver and the presence of toxemia, which causes liver metabolism disorders.\(^\text{25}\)

In our patient, insufficient milk production during the first three days may have played a role in the cause of jaundice in this baby (what we call breastfeeding jaundice).\(^\text{26}\) Breastfeeding jaundice occurs on days 2 through 5.\(^\text{27,28}\) A study in a tertiary referral hospital in West Java before the COVID-19 pandemic found that the most common etiology of neonatal jaundice was physiological (23.2%). Other causes included neonatal hepatitis (14.7%), other hemolytic causes (13.7%), infection (12.6%), ABO incompatibility (11.6%), and breastfeeding (11.6%).\(^\text{29}\)

Early adequate feeding is an important and fundamental issue that must be considered in newborns, including when

| Laboratory examination | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 |
|------------------------|---|---|---|---|---|---|---|---|---|----|----|----|
| Hemoglobin, g/dL        | 16.8 | – | – | – | 17.4 | 15.2 | – | – | – | – | – | – |
| Hematocrit, %           | 49.2 | – | – | – | 48.4 | 41.1 | – | – | – | – | – | – |
| Leukocyte count, leukocytes/mm\(^3\) | 9,800 | – | – | – | 11,200 | 11,500 | – | – | – | – | – | – |
| Platelet count, platelets/mm\(^3\) | 285,000 | – | – | – | 194,000 | 90,000 | – | – | – | – | – | – |
| NLR                     | 3.6 | – | – | – | – | – | – | – | – | – | – | – |
| TLC, \(\mu\)L           | 2,116 | – | – | – | 3,539 | 4,611.5 | – | – | – | – | – | – |
| CRP, mg/L               | < 6 | – | – | – | 12 | 24 | – | – | – | – | – | – |
| aPTT, s                 | – | – | – | 26.3 (26.1) | – | – | – | – | – | – | – | – |
| PT, s; (INR)            | – | – | – | 1.09 (0.7–1.2) | – | – | – | – | – | – | – | – |
| Fibrinogen, mg/dL       | – | – | – | 363.6 | – | – | – | – | – | – | – | – |
| D-dimer, mg/mL          | – | – | – | 3,340 | – | – | – | – | – | – | – | – |
| Total bilirubin, mg/dL  | – | 13.6 | – | – | 16 | 7.1 | – | – | – | – | – | – |
| Direct bilirubin, mg/dL | – | 1 | – | – | 2.1 | 1 | – | – | – | – | – | – |
| Indirect bilirubin, mg/dL | – | 12.6 | – | – | 13.9 | 5.95 | – | – | – | – | – | – |

\(\text{aPTT} = \text{activated partial thromboplastin time}; \text{CRP} = \text{C-reactive protein}; \text{INR} = \text{international normalized ratio}; \text{NLR} = \text{neutrophil lymphocyte ratio}; \text{PT} = \text{prothrombin time}; \text{TLC} = \text{total lymphocyte count.}\)
we face new diseases such as COVID-19. In addition to being able to prevent jaundice, early adequate feeding can also prevent clinical worsening of the disease and its associated risk of mortality. Therefore, if physicians focus only on new hypotheses about the cause of jaundice, this could result in a harmful situation.

In septic patients, the etiopathology of hyperbilirubinemia usually also results in hemolysis. Although the etiology has some differences, both show the same trend of increased bilirubin levels, starting with an increase in indirect bilirubin (unconjugated bilirubin) followed by an increase in direct bilirubin (conjugated bilirubin). This increase is correlated with

**TABLE 3**

Comparison of neonatal sepsis and COVID-19

| Patient no. | Clinical features | Neonatal sepsis | COVID-19 |
|-------------|------------------|----------------|----------|
| 1           | Temperature irregularity | Hypothermia (early onset), hyperthermia (late onset) | Hyperthermia/persistent high temperature |
| 2           | Change in behavior | Lethargy, irritability, change in tone | Lethargy, irritability, change in tone |
| 3           | Skin | Poor peripheral perfusion, cyanosis, mottling, pallor, petechiae, rashes, sclerema, or jaundice singularly or in combination | Rash |
| 4           | Feeding problems | Feeding intolerance, vomiting, diarrhea, or abdominal distention | Poor feeding, vomiting, diarrhea |
| 5           | Cardiopulmonary | Tachypnea, respiratory distress, tachycardia, hypotension | Cough, rhinitis, respiratory distress |
| 6           | Metabolic | Hypoglycemia, hyperglycemia, metabolic acidosis | Metabolic acidosis |
| 7           | Focal infections | Cellulitis, impetigo, soft tissue abscesses, omphalitis, conjunctivitis, otitis media, meningitis, or osteomyelitis | No focal infection |
| 8           | Laboratory findings | Leukocytosis/eukopenia, neutropenia, ratio of immature to total polymorphonuclear cells > 0.2, increased C-reactive protein, increased procalcitonin | Lymphopenia, thrombocytosis, neutropenia, increased liver function, elevated C-reactive protein, increased D-dimer level, coagulopathy |
| 9           | Radiological findings | Normal/infiltrate | Ground-glass appearance |
worsening of the disease.\textsuperscript{24,32} Our patient was treated with phototherapy and ursodeoxycholic acid, which is the standard drug for cholestasis management.\textsuperscript{33}

There is no specific drug treatment of SARS-CoV-2 for neonates.\textsuperscript{1} Symptomatic and supportive treatment, including oxygen supplementation and maintenance of hydration, electrolytes, and acid–base balance, are the mainstay therapies for patients with SARS-CoV-2 infection. Supplementation with water and electrolytes should be appropriate to avoid aggravating pulmonary edema and reducing oxygenation.\textsuperscript{7}

Antibiotic therapy for susceptible organism is usually given for 7 to 10 days, and should be discontinued immediately after clinical improvement and negative blood culture results. Neonates with persistent, complicated infections may require a longer duration of antibiotic treatment. It is important to stop antibiotics after a bacterial infection is sufficiently ruled out. In our patient, antibiotics were stopped after 7 days.\textsuperscript{3,9}

The U.S. Food and Drug Administration has approved remdesivir for neonates weighing more than 3,500 g.\textsuperscript{34} In this case, our patient weighed less than 3,500 g and evidenced hyperbilirubinemia. The administration of remdesivir is not included in the protocol of COVID-19 in children and neonates in Indonesia. Our patient was discharged after resolution of respiratory symptoms and fever, with clinical stability, and after two negative nasal swabs for SARS-CoV-2 acquired 48 hours apart.

We suggest that the screening of infants born from mothers with confirmed COVID-19 or suspected COVID-19 is critical. Neonates who are positive for COVID-19 need thorough symptomatic and supportive treatment, including antibiotics, and adequate early feeding are fundamental issues that need attention in newborns with COVID-19 to prevent complications that aggravate the disease.

Received July 3, 2021. Accepted for publication January 21, 2022.

Acknowledgments: We thank the NICU team, especially Health Workers and COVID-19 Team of Robert Walter Mongisidi Army Hospital and Pediatric Resident Sam Ratuani University. The American Society of Tropical Medicine and Hygiene has waived the open-access fee for this article due to the ongoing COVID-19 pandemic and has assisted with publication expenses.

Author’s addresses: Suryadi Nikolaas Napoleon Tatura, Division of Pediatric Infection and Tropical Medicine, Department of Pediatrics, Faculty of Medicine, Sam Ratuani University, Manado, Indonesia, Department of Pediatrics, Prof. R.D. Kandou General Hospital, Manado, North Sulawesi, Indonesia, and Department of Pediatrics, Robert Walter Mongisidi Army Hospital, Manado, North Sulawesi, Indonesia, E-mail: nicoia_n_sur@yahoo.co.id.

This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

REFERENCES

1. SATGAS COVID-19 Indonesia, 2021. Kementerian Kesehatan Republik Indonesia. Available at: https://covid19.go.id/peta-sebaran-covid19. Accessed July 25, 2021.

2. Ministry of Women’s Empowerment and Child Protection of the Republic of Indonesia [Kementerian Pemberdayaan Perempuan dan Perlindungan Anak Republik Indonesia], 2021. Profil Anak Indonesia Tahun 2020. Available at: https://www.kemenppa.go.id/index.php/page/read/25/3056/profil-anak-indonesia-tahun-2020. Accessed February 8, 2022.

3. Korang SK, Safi S, Gluud C, Thomesen UL, Jakobsen JC, 2019. Antibiotic regimens for neonatal sepsis: a protocol for systematic review with meta-analysis. Syst Rev 8: 306.

4. Kementerian Kesehatan Republik Indonesia, 2021. Profil Kesehatan Indonesia Tahun 2020. Jakarta: Kementerian Kesehatan RI.

5. Undururraga EA, Chowell G, Mizumoto K, 2021. COVID-19 case fatality risk by age and gender in a high testing setting in Latin America: Chile, March–August 2020. Infect Dis Poverty 10: 11–22.

6. Barrero-Castillero A, Beam KS, Bernardini LB, Ramos EG, Daveport PE, Duncan AR, 2021. COVID-19: neonatal–perinatal perspectives. J Perinatol 41: 940–951.

7. Lu Q, Shi Y, 2020. Coronavirus disease (COVID-19) and neonates: what neonatologists need to know. J Med Virol 92: 564–567.

8. Wang J, Qi H, Bao L, Li F, Shi Y, 2020. A contingency plan for the management of the 2019 novel coronavirus outbreak in neonatal intensive care units. Lancet Child Adolesc Health 4: 258–259.

9. Cherry H, Kaplan S, Hotez PJ, eds., 2014. Feigin and Cherry’s Textbook of Pediatric Infectious Disease, 7th edition. Philadelphia, PA: Elsevier Saunders.

10. Laing AG, Lorenc A, Barrio IDMD, Das A, Fish M, Monin L, 2020. A consensus COVID-19 immune signature combines immuno-protection with discrete sepsis-like traits associated with prognosis. medRx. https://doi.org/10.1101/2020.06.08.2025112.

11. Gomella TL, Cunningham MD, Eyal FG, Tuttle DJ, eds., 2013. Neonatology: Management, Procedures, On-Call Problems, Diseases, and Drugs. New York, NY: McGraw-Hill Education Medical.

12. WHO, 2021. Definition and Categorization of the Timing of Mother to Child Transmission of SARS CoV2: Scientific Brief. Geneva, Switzerland: World Health Organization, 1–14.

13. Kotlyar AM, Grechukhina O, Chen A, Popkhadze S, Grimshaw A, Tal O, Taylor HS, Tal R, 2020. Vertical transmission of coronavirus disease 2019: a systematic review and meta-analysis. Am J Obstet Gynecol 224: 35–53.

14. Zamaniyan M, Ebad, A, Aghajanpoor S, Rahmani Z, Haghshenas M, Azzi S, 2020. Preterm delivery in pregnant woman with critical COVID-19 pneumonia and vertical transmission. Prenat Diagn 10: 1002.

15. Eastin C, Eastin T, 2020. Epidemiological characteristics of 2143 patients with 2019 coronavirus disease in China. J Emerg Med 58: 712–713.

16. Hinojosa-Velasco A et al., 2020. A case report of newborn infant with severe COVID-19 in Mexico: detection of SARS-CoV-2 in human breast milk and stool. Int J Infect Dis 100: 21–24.

17. Cai J et al., 2020. A case series of children with 2019 novel coronavirus infection: clinical and epidemiological features. Clin Infect Dis 71: 1547–1551.

18. Dong Y, Chi X, Hai H, Sun L, Zhang M, Xie WF, Chen W, 2020. Antibodies in the breast milk of a maternal woman with COVID-19. Emerg Microbes Infect 9: 1467–1469.

19. Mark EG, Golden WC, Gilmore MM, Sick-Samuels A, Curless MS, Nogee LM, Milestone AM, Johnson J, 2021. Community-onset severe acute respiratory syndrome coronavirus 2 infection in young infants: a systematic review. J Pediatr 228: 94–100.

20. Wu Q, Xing Y, Shi L, Li W, Gao Y, Pan S, Wang Y, Wang W, Xing Q, 2020. Coinfection and other clinical characteristics of COVID–19 in children. Pediatrics 146: e20200961.

21. Trevisanuto D, Cavallin F, Cavicchiolo ME, Borellini M, Calgaro S, Baraldi E, 2021. Coronavirus infection in neonates: a systematic review. Arch Dis Child Fetal Neonatal Ed 106: 330–335.

22. Greco C et al., 2016. Neonatal jaundice in low and middle-income countries: lessons and future directions from the 2015 Don Ostrow Trieste Yellow Retreat. Neonatology 110: 172–180.

23. Olusanya BO, Kaplan M, Hansen TWR, 2018. Neonatal hyperbilirubinemia: a global perspective. Lancet Child Adolesc Health 2: 610–620.
24. Zhao B et al., 2020. Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids. *Protein Cell* 11: 771–775.
25. Radford JA, Rhodes FA, 1967. The association of jaundice with lobar pneumonia in the territory of Papua and New Guinea. *Med J Aust* 2: 678–681.
26. Gartner LM, 2001. Breastfeeding and jaundice. *J Perinatol* 21: S25–S29.
27. Maisels MJ, 2006. Neonatal jaundice. *Pediatrics* 27: 443–454.
28. Pan DH, Rivas Y, 2017. Jaundice: newborn to age 2 months. *Pediatrics* 38: 499–510.
29. Yahya N, Yuniati T, Lubis L, 2017. Characteristics of neonatal hyperbilirubinemia at West Java’s top referral hospital, Indonesia. *Althea Med J* 4: 167–172.
30. Edmond KM, Kirkwood BR, Amenga-Etego S, Owusu-Agyei S, Hurt LS, 2007. Effect of early infant feeding practices on infection-specific neonatal mortality: an investigation of the causal links with observational data from rural Ghana. *Am J Clin Nutr* 86: 1126–1131.
31. Portincasa P, Krawczyk M, Machill A, Lammert F, Ciaula AD, 2020. Hepatic consequences of COVID-19 infection: lapping or bitting? *Eur J Intern Med* 77: 18–24.
32. Nesseler N, Launey Y, Aninat C, Morel F, Malledant Y, Seguin P, 2012. Review: the liver in sepsis. *Crit Care* 235: 1–8.
33. Lewis T, Kuye S, Sherman A, 2018. Ursodeoxycholic acid versus phenobarbital for cholestasis in the neonatal intensive care unit. *BMC Pediatr* 18: 197–203.
34. Gilead Sciences, 2022. Fact Sheet for Healthcare Providers: Emergency Use Authorization (EUA) of Veklury® (Remdesivir) for the Treatment of Coronavirus Disease 2019 (COVID-19) in Pediatric Patients Weighing 3.5 kg to Less Than 40 kg or Pediatric Patients Less Than 12 Years of Age Weighing at Least 3.5 kg, with Positive Results of Direct SARS-CoV-2 Viral Testing Who Are: Hospitalized, or Not Hospitalized and Have Mild-to-Moderate COVID-19, and Are at High Risk for Progression to Severe COVID-19, Including Hospitalization or Death. Available at: https://www.fda.gov/media/137566/download. Accessed February 8, 2022.